1932

Abstract

Adenosine accumulation during ischemia and inflammation protects tissues from injury. In ischemic tissues adenosine accumulates due to inhibition of adenosine kinase, and in inflamed tissues adenosine is formed from adenine nucleotides that are released from many cells including platelets, mast cells, nerves, and endothelium. Nucleotides are rapidly converted to adenosine by a family of ecto-nucleotidases including CD39 and CD73. Activation of A and possibly A adenosine receptors (ARs) protects heart and other tissues by preconditioning through a pathway including protein kinase C and mitochondrial K channels. Activation of A receptors limits reperfusion injury by inhibiting inflammatory processes in neutrophils, platelets, macrophages and T cells. Adenosine produces proinflammatory responses mediated by receptors that vary among species; A and A receptors mediate degranulation of rodent and human or canine mast cells, respectively. Novel adenosine receptor subtype–selective ligands have recently been developed. These include MRS1754 (A blocker), MRS1220 (A blocker), MRE 3008F20 (human A blocker), MRS1523 (rat A blocker), and ATL146e (A agonist). These new pharmacologic tools will help investigators to sort out how adenosine protects tissues from injury and to identify new therapeutic agents that hold promise for the treatment of inflammatory and ischemic diseases.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.41.1.775
2001-04-01
2024-04-24
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.41.1.775
Loading
/content/journals/10.1146/annurev.pharmtox.41.1.775
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error